User profiles for Torsten Gerriet Blum

Dr. Torsten Blum

Klinik für Pneumologie, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring
Verified email at helios-gesundheit.de
Cited by 2934

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo …

…, SM Huhn, J Richter, U Neff, TG Blum… - The Lancet …, 2021 - thelancet.com
Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

ESR/ERS statement paper on lung cancer screening

HU Kauczor, AM Baird, TG Blum, L Bonomo… - European …, 2020 - Springer
In Europe, lung cancer ranks third among the most common cancers, remaining the biggest
killer. Since the publication of the first European Society of Radiology and European …

[HTML][HTML] Morphometrical analysis of transbronchial cryobiopsies

…, N Schönfeld, TT Bauer, T Mairinger, TG Blum… - Diagnostic …, 2011 - Springer
The recent introduction of bronchoscopically recovered cryobiopsy of lung tissue has opened
up new possibilities in the diagnosis of neoplastic and non-neoplastic lung diseases in …

[HTML][HTML] Diagnostic yield of transbronchial cryobiopsy in non-neoplastic lung disease: a retrospective case series

S Griff, N Schönfeld, W Ammenwerth, TG Blum… - BMC pulmonary …, 2014 - Springer
Background Due to the small amount of alveolar tissue in transbronchial biopsy (TBB) by
forceps, the diagnosis of diffuse, parenchymal lung diseases (DPLD) is inherently problematic, …

[HTML][HTML] Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: The eNRGy1 global multicenter registry

…, S Ali, V Gounant, F Magne, TG Blum… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Although NRG1 fusions are oncogenic drivers across multiple tumor types
including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 …

European Respiratory Society guideline on various aspects of quality in lung cancer care

TG Blum, RL Morgan, V Durieux… - European …, 2023 - Eur Respiratory Soc
This European Respiratory Society guideline is dedicated to the provision of good quality
recommendations in lung cancer care. All the clinical recommendations contained were based …

[HTML][HTML] Autoimmune disorders and paraneoplastic syndromes in thymoma

TG Blum, D Misch, J Kollmeier, S Thiel… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Thymomas are counted among the rare tumour entities which are associated with
autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other …

Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer–A multicenter observational analysis

N Frost, K Unger, TG Blum, D Misch, S Kurz, H Lüders… - Lung Cancer, 2023 - Elsevier
Introduction Checkpoint-inhibitor pneumonitis (CIP) represents a major immune-related
adverse event (irAE) in patients with lung cancer. We aimed for the clinical characterization, …

[HTML][HTML] Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their …

…, J Chorostowska-Wynimko, TG Blum… - ERJ Open …, 2023 - Eur Respiratory Soc
7 years on from the European Society of Radiology (ESR)/European Respiratory Society (ERS)
white paper on lung cancer screening, which recommended low-dose computed …

NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.

…, SM Ali, F Magne, I Monnet, D Moro-Sibilot, TG Blum… - 2019 - ascopubs.org
9081 Background: NRG1 fusions are potentially actionable driver events enriched in NSCLCs,
particularly invasive mucinous adenocarcinomas (IMAs). These fusions activate HER3/…